Abstract: The invention described herein provides biological markers for the diagnosis, prognosis, and monitoring of prostate cancer

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an IL-12/IL-23 inhibitor.

Abstract: The present application provides compositions and methods for producing antigen presenting cells (APCs) from monocytes (e.g., monocytes from cancer patients) that involve an IL-10 receptor activator (e.g., IL-10), IFN? receptor activator (e.g., IFN?), TNF? receptor activator (e.g., TNF?), IL-4 receptor activator (e.g., IL-4), GM-CSF receptor activator (e.g., GM-CSF), and/or IL-6 receptor activator (e.g., IL-6). APCs produced accordingly are also provided, as well as methods of activating immune cells (e.g., T cells) via co-culturing with APCs. The activated immune cell compositions and the methods of treatments that involve the activated immune cells are also provided.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an immunosuppressant.

Abstract: The invention described herein provides biological markers for the diagnosis, prognosis, and monitoring of prostate cancer

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a JAK or other kinase inhibitor.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an immunosuppressant.

Abstract: This invention provides a set of biological markers that are useful for detecting cancer. This invention further provides methods of using those biological markers for the diagnosis, prognosis, or monitoring of cancer.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an immune modulatory agent (e.g., a CD40/CD40L inhibitor).

Abstract: The present disclosure relates to compositions and methods for assessing prostate cancer (e.g., identification of the aggressiveness or indolence of prostate cancer) in a subject. The compositions and methods include obtaining subject specific information (e.g., age, digital rectal exam (DRE) data, prostate volume, prostate density, total prostate-specific antigen (PSA)) and obtaining a biological sample from a subject and determining a measurement for a panel of biomarkers in the biological sample. Compositions and methods of the disclosure find use in both clinical and research settings, for example, within the fields of biology, immunology, medicine, and oncology.

Abstract: The present disclosure relates to compositions, methods, and systems useful for assessing whether a patient with prostate cancer is a candidate for active surveillance of the prostate cancer, as well as compositions, methods, and systems for assessing and identifying prostate cancer. The disclosure provides algorithm-based assays comprising subtraction-normalized immunocyte signature profiling from a sample obtained from a prostate cancer patient. Measurement of expression of signature markers identify on an individual basis, via an active surveillance risk score, prostate cancer patients that are to enter, continue, or stop an active surveillance pathway.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a JAK inhibitor.

Abstract: This invention provides a set of biological markers that are useful for detecting cancer. This invention further provides methods of using those biological markers for the diagnosis, prognosis, or monitoring of cancer.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a JAK inhibitor.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a TNF-alpha inhibitor.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an immunosuppressant.

Abstract: The invention described herein provides biological markers for the diagnosis, prognosis, and monitoring of prostate cancer

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an IL-12/IL-23 inhibitor.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with IL-10 or an IL-10 agonist.

Abstract: The invention described herein provides biological markers for the diagnosis, prognosis, and monitoring of prostate cancer.